Penumbra vs Teleflex
PEN and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PEN and TFX compare
Penumbra is the larger company, worth 2.1 times as much as Teleflex ($12.6B against $5.9B).
Teleflex grew revenue faster over the last twelve months (30.7% versus 17.0% for Penumbra).
Penumbra keeps more of each dollar of sales as profit, with a net margin of 10.1% compared with −45.8% at Teleflex.
Teleflex pays a dividend yielding 0.97%; Penumbra does not pay one.
Penumbra scores higher on the StockData Score (15 against 7 for Teleflex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PEN | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $12.6B | $5.9B |
| Share price | $318.95 | $139.77 |
| Change, 1 year | 36.7% | 9.1% |
| Change, 5 years | 11.8% | −60.4% |
| Beta (5Y) | 0.87 | 0.85 |
| Employees | 4,700 | 16K |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 80.3× | – |
| P/S | 8.1× | 2.6× (better) |
| P/B | 7.9× | 2.0× (better) |
| EV/EBITDA | 56.8× | 43.7× (better) |
| P/FCF | 62.7× | 35.2× (better) |
| FCF yield | 1.6% | 2.8% (better) |
| Fair value | $184.29 | $36.02 |
| Margin of safety | −73.1% (better) | −288% |
| Growth | ||
| Revenue growth (TTM) | 17.0% | 30.7% (better) |
| Revenue growth, 5Y average | 20.2% (better) | −4.7% |
| Net income growth (TTM) | −4.3% (better) | −638% |
| EPS growth (TTM) | −4.1% (better) | −645% |
| Profitability | ||
| Gross margin | 68.0% (better) | 54.9% |
| Operating margin | 12.1% (better) | 2.0% |
| Net margin | 10.1% (better) | −45.8% |
| FCF margin | 12.8% (better) | 7.5% |
| Return on equity | 10.7% (better) | −28.9% |
| Return on invested capital | 15.9% (better) | 0.62% |
| Financial health | ||
| Debt / equity | 0.00 | 0.97 (better) |
| Net debt / EBITDA | – | 13.01 |
| Interest coverage | 149× (better) | 0.4× |
| Current ratio | 5.89 (better) | 2.60 |
| Altman Z-score | 19.07 (better) | 1.47 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.97% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 4.2% |
| Shareholder yield | 0.00% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 86.7% | 113% |
| Held by insiders | 3.4% | 0.73% |
| Insider net buying, 12 months | −$11.1M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 5.9% | 9.6% |
Go deeper
- PEN stock overview
- PEN income statement
- PEN valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.